Theragnostic Technologies Inc.

We develop multifunctional nanotechnology-based products for diagnostic, therapeutic & regenerative medicine. First product ManGraDex is MRI contrast agent.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stony Brook, NY, US
  • Currency USD
  • Founded 2012
  • Employees 3
  • Website theragnostictechnologies.com

Company Summary

Summary:
-Three highly differentiated platform technologies with diverse category and product candidates.

- First product focus: Ground breaking MRI contrast agent ManGraDex >$5 Billion MRI contrast market.

-Strong IP with significant portfolio expansion potential across genitourinary, cardiovascular, cancer and musculoskeletal spaces.

-Multiple value enhancing milestones with First-In-Human Trials application in mid 2017.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free